Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join Class Action Lawsuit

NEW YORK, NEW YORK / ACCESSWIRE / July 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, an internationally renowned law firm, notifies investors of the filing of a class action lawsuit against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ:ALT) and certain of its principals.

Class definition:

This lawsuit seeks to recover damages from Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s website at bgandg.com/ALT.

Case details:

The complaint alleges that throughout the duration of the lawsuit, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Altimmune exaggerated the potential of pemwidutide to differentiate itself from competing GLP-1 agonists based on the efficacy and tolerability results observed in the MOMENTUM study; (2) as a result, the results of the MOMENTUM study were less material to the clinical, commercial, and competitive prospects of pemwidutide than defendants led investors to believe; (3) as a result of all of the foregoing, defendants exaggerated the prospects of Altimmune to find a strategic partner to develop pemwidutide; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

What’s next?

The class action lawsuit has already been filed. If you would like to review a copy of the complaint, you can visit the firm’s website at bgandg.com/ALT or contact Peretz Bronstein, Esq. or his Client Relationship Manager, Nathan Miller of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in the Altimmune case, you have until July 5, 2024 to ask the Court to appoint you as lead plaintiff. Your ability to share in any award does not require you to serve as lead plaintiff.

There is no cost to you.

We represent investors in class action lawsuits on a contingency basis. This means that we will ask the court to recover our costs and attorney fees, usually a percentage of the total award, only if we are successful.

Why Bronstein, Gewirtz and Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm representing investors in securities fraud class actions and shareholder derivative lawsuits. Our firm has recovered hundreds of millions of dollars for investors across the country.

Lawyer Advertising. Previous results do not guarantee similar results.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | (email protected)

SOURCE: Bronstein, Gewirtz and Grossman, LLC